Edition:
United Kingdom

Diffusion Pharmaceuticals Inc (DFFN.OQ)

DFFN.OQ on NASDAQ Stock Exchange Capital Market

1.99USD
9:00pm BST
Change (% chg)

$-0.10 (-4.78%)
Prev Close
$2.09
Open
$2.10
Day's High
$2.10
Day's Low
$1.96
Volume
6,732
Avg. Vol
65,931
52-wk High
$10.98
52-wk Low
$1.85

Latest Key Developments (Source: Significant Developments)

Diffusion Pharmaceuticals Says Qtrly Loss Per Share $0.63
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Diffusion Pharmaceuticals Inc ::DIFFUSION PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.DIFFUSION PHARMACEUTICALS INC - PHASE 2 ON-AMBULANCE TSC CLINICAL TRIAL FOR TREATMENT OF STROKE READY TO ENROLL.DIFFUSION PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.63.  Full Article

U.S. Awards Diffusion Rights For Use Of TSC Along With Stroke Therapeutic
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Diffusion Pharmaceuticals Inc ::U.S. PATENT OFFICE AWARDS DIFFUSION EXCLUSIVE RIGHTS FOR USE OF TSC IN CONJUNCTION WITH ONLY FDA-APPROVED STROKE THERAPEUTIC.  Full Article

Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Diffusion Pharmaceuticals Inc ::DIFFUSION PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.DIFFUSION PHARMACEUTICALS INC - HAD CASH AND CASH EQUIVALENTS OF $11.0 MILLION AS OF SEPTEMBER 30.DIFFUSION PHARMACEUTICALS - BELIEVES CASH AND CASH EQUIVALENTS AT SEPT 30 ARE SUFFICIENT TO FUND OPERATIONS THROUGH SEPT 2019.DIFFUSION PHARMACEUTICALS - RECOGNIZED NON-CASH GOODWILL IMPAIRMENT CHARGE OF $4.2 MILLION IN QUARTER.DIFFUSION PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.13.  Full Article

Diffusion Pharmaceuticals ‍Had Cash And Cash Equivalents Of $8.9 Mln AS OF Dec 31, 2017​
Tuesday, 3 Apr 2018 

April 3 (Reuters) - Diffusion Pharmaceuticals Inc ::DIFFUSION PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.‍HAD CASH AND CASH EQUIVALENTS OF $8.9 MILLION AS OF DECEMBER 31, 2017​.  Full Article

Diffusion Pharmaceuticals Files Prospectus Related To Offering Of Common Stock
Tuesday, 6 Feb 2018 

Feb 6 (Reuters) - Diffusion Pharmaceuticals Inc ::DIFFUSION PHARMACEUTICALS INC FILES PROSPECTUS RELATED TO OFFERING UP TO 12.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING‍​.  Full Article

Diffusion Pharma Files For Stock Offering For Up To About $15 Mln
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Diffusion Pharmaceuticals Inc ::DIFFUSION PHARMACEUTICALS FILES FOR STOCK OFFERING FOR UP TO ABOUT $15 MILLION - SEC FILING.  Full Article

Diffusion Pharmaceuticals reports qtrly net income per diluted share $0.20‍​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Diffusion Pharmaceuticals Inc :Diffusion Pharmaceuticals Inc qtrly net income per diluted share $0.20‍​.Diffusion Pharmaceuticals Inc - ‍remain on track to begin enrolling patients by end of 2017 for tsc glioblastoma phase 3 pivotal study​.Diffusion Pharmaceuticals Inc - ‍awaiting confirmation from Nasdaq that co demonstrated compliance with all applicable requirements for continued listing​.  Full Article

Diffusion Pharma gets FDA protocol guidance for phase 3 trial with TSC
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Diffusion Pharmaceuticals Inc :Diffusion Pharmaceuticals receives final FDA protocol guidance for phase 3 clinical trial with TSC in patients newly diagnosed with inoperable glioblastoma multiforme.Has responded to all outstanding points raised by FDA, plans to begin trial under protocol agreed to by FDA by end of 2017​.Trial to compare survival at 2 yrs of patients receiving TSC concurrent with chemo, radiation with patients receiving SOC alone​.  Full Article